Illumina Inc. ($ILMN) Stock Forecast: Up 6.1% Today

What is Illumina Inc.?

Illumina (ILMN) is a leading biotechnology company recognized for its contributions to genetic sequencing and array-based technologies. The company boasts a market capitalization of $19.94 billion and has demonstrated strong performance for the past twenty years.

Why is Illumina Inc. going up?

ILMN stock is up 6.1% on Sep 13, 2024 13:50

• Illumina (ILMN) exhibited a notable bullish trend today, likely influenced by:
• Recognition of the stock's impressive long-term performance, drawing in investors seeking stable returns.
• Mention of a recent earnings surge, potentially boosting confidence in the company's growth outlook and attracting more buyers.
• Positive market sentiment towards Illumina's innovative technologies and the promising opportunities within the biotech industry.

ILMN Price Chart

ILMN News

$1000 Invested In This Stock 20 Years Ago Would Be Worth $38,000 Today - Illumina ( NASDAQ:ILMN )

Illumina ILMN has outperformed the market over the past 20 years by 11.63% on an annualized basis producing an average annual return of 19.91%. Currently, Illumina has a market capitalization of $19.94 billion.

https://www.benzinga.com/insights/news/24/09/40821203/1000-invested-in-this-stock-20-years-ago-would-be-worth-38-000-today

Bull of the Day: Illumina ( ILMN )

Big jump after earnings led by a pullback, could be an opportunity here.

https://www.zacks.com/commentary/2333703/bull-of-the-day-illumina-ilmn

Trending Today

Memecoin ($MEME) Crypto Forecast: Up 5.4% Today

NEO ($NEO) Crypto Forecast: Up 5.3% Today

Nervos Network ($CKB) Crypto Forecast: Down 5.3% Today

Aptos ($APT) Crypto Forecast: Up 9.6% Today

Pepe ($PEPE) Crypto Forecast: Up 8.0% Today

Wormhole ($W) Crypto Forecast: Up 5.1% Today

Bittensor ($TAO) Crypto Forecast: Up 12.9% Today

Ethereum ($ETH) Crypto Forecast: Up 5.3% Today

Arbitrum ($ARB) Crypto Forecast: Up 7.2% Today

Floki ($FLOKI) Crypto Forecast: Up 5.7% Today

Illumina Inc. Price History

13.08.2024 - ILMN Stock was up 6.1%

• Illumina (ILMN) exhibited a notable bullish trend today, likely influenced by:
• Recognition of the stock's impressive long-term performance, drawing in investors seeking stable returns.
• Mention of a recent earnings surge, potentially boosting confidence in the company's growth outlook and attracting more buyers.
• Positive market sentiment towards Illumina's innovative technologies and the promising opportunities within the biotech industry.

10.06.2024 - ILMN Stock was up 7.9%

• The acquisition of Fluent BioSciences by Illumina is favorably viewed by investors, reflecting confidence in the company's strategic growth plans, particularly in single-cell analysis and multiomics research.
• This positive market response indicates that investors perceive the acquisition as a move that will bolster Illumina's standing in the genomics field, potentially resulting in enhanced market share and revenue growth.
• Despite a decline in 10x Genomics stock following the Illumina deal and a downgrade from Deutsche, Illumina's stock surge suggests investors are prioritizing the long-term advantages of the acquisition over short-term market fluctuations.
• Illumina's bullish momentum today is driven by its dedication to innovation and expansion in critical research domains, indicating a promising outlook for its future growth trajectory.

11.06.2024 - ILMN Stock was up 5.2%

• Illumina's acquisition of Fluent Biosciences to enhance its single-cell analysis technology portfolio positively impacted investor sentiment, leading to a bullish market movement for ILMN.
• The strategic move to expand into single-cell analysis and multiomics research showcased Illumina's commitment to innovation and market expansion, further boosting investor confidence.
• The acquisition news causing a decline in 10x Genomics stock suggests that investors may view Illumina's advancements as a threat to competitors, potentially contributing to the bullish trend in ILMN's stock price.
• Overall, Illumina's strategic acquisition and focus on technological advancements in the biotech sector likely played a significant role in today's bullish market movement for the company.

16.06.2024 - ILMN Stock was up 5.1%

• The acquisition of Fluent Biosciences by Illumina adds single-cell analysis technology to its portfolio.
• Illumina has strategically expanded its reach in single-cell analysis and multiomics research through acquisitions, positively impacting investor sentiment.
• The bullish market movement may be influenced by the positive performance of the biotech sector, with companies like Nvidia leading the Nasdaq and S&P 500 to record high closes.
• The slipping of 10x Genomics stock as Illumina acquires a competitor might have further boosted confidence in Illumina's growth prospects and market position.

16.06.2024 - ILMN Stock was up 6.2%

• The uptick in Illumina's stock value may be linked to the imminent release of its second-quarter financial results, causing optimistic reactions from investors who anticipate a robust performance.
• The recent acquisition of Fluent Biosciences, which enhances its range with single-cell analysis technology, likely played a role in the stock's upsurge, showcasing strategic expansion and product diversification.
• The general positive market atmosphere, marked by new highs in Nasdaq and S&P 500 indices, probably additionally supported Illumina's stock, especially considering favorable remarks on potential rate adjustments by Powell and the sound showings of tech peers like Nvidia and Apple.

07.07.2024 - ILMN Stock was up 5.4%

• Better-than-expected second-quarter sales results were reported by Illumina, leading to an increase in analyst forecasts and a bullish movement in the stock.
• Citigroup raised Illumina's stock target and maintained a positive rating due to strong margins, further boosting investor confidence.
• Despite a revenue decline amid market challenges, Illumina managed to improve its margins, which was well-received by investors and contributed to the bullish movement in the stock.
• The positive earnings report and analyst upgrades likely fueled investor optimism and drove the stock higher throughout the trading day.

07.07.2024 - ILMN Stock was up 8.0%

• The bullish movement in Illumina's stock today is attributed to positive news and performance indicators:
• Citigroup raised the stock target and maintained a strong rating based on robust margins.
• Despite market challenges, the company improved its margins, which is likely viewed positively by investors.
• Illumina's Q2 earnings and revenues surpassed estimates significantly, indicating strong financial performance.
• The reported loss in the second quarter might have been overshadowed by the positive aspects of improved margins and exceeding earnings expectations, leading to the bullish market movement.

13.07.2024 - ILMN Stock was down 5.2%

• Illumina reported surpassing Q2 earnings expectations, although it adjusted its 2024 sales forecast downwards, reflecting difficulties within the global macroeconomic landscape.
• Anticipating a decrease in yearly sales within its primary segment due to constraints in biotech funding, Illumina's future outlook is affected.
• Despite the negative stock movement, analysts have raised their price target for Illumina, showcasing faith in the company's potential longevity.
• The downward movement in Illumina's stock is possibly linked to a blend of factors including the mixed earnings report, revised sales forecast, and uncertainties surrounding future demand in the gene sequencing industry amidst biotech funding challenges.

05.07.2024 - ILMN Stock was up 5.3%

• The stock of Illumina experienced a significant bullish movement recently.
• The company's launch of a new oncology menu for NovaSeq X Series customers indicates a focus on expanding its oncology testing capabilities, which might have influenced positive investor sentiment.
• Market anticipation of Illumina outperforming earnings estimates for the quarter ended June 2024 likely supported the bullish trend, reflecting investor confidence in the company's financial performance.
• Negative sentiment expressed towards Illumina on a financial program might have initially caused some uncertainty, but the overall market response has been largely positive, possibly driven by advancements in Illumina's product offerings and financial outlook.

08.07.2024 - ILMN Stock was up 5.6%

• Illumina's shares surged as analysts increased their price targets post strong Q2 results, indicating confidence in the company's performance and growth potential.
• The decision to raise Illumina's stock target, coupled with a maintained strong rating from Citi, underscores a positive view on the company's profitability and margins.
• Despite a revenue dip due to market challenges, Illumina enhanced its margins, demonstrating resilience and effective cost management.
• The upward trend in Illumina's stock value can be attributed to improved financial performance, optimistic analyst predictions, and overall market positivity propelling the stock upwards.

14.07.2024 - ILMN Stock was up 5.6%

• Illumina, Inc. received a reaffirmation of a "Buy" rating, with new product launches boosting the growth outlook, which likely contributed to the bullish movement.
• Despite beating Q2 earnings expectations, Illumina lowered its 2024 sales view, indicating potential concerns about future performance.
• Activist pressure could be driving some market excitement and speculation around potential strategic changes within the company.
• The overall positive sentiment around gene editing stocks and the potential for transformative medicine may have also positively influenced Illumina's stock performance today.

15.07.2024 - ILMN Stock was up 5.1%

• Illumina's solid performance over the past 20 years, with an annualized return of 21.21%, likely contributed to the bullish movement today.
• The reaffirmation of a "Buy" rating by a prominent analyst, citing new product launches boosting growth outlook, could have instilled confidence in investors and further fueled the positive momentum.
• Despite surpassing Q2 earnings expectations, the update on lowering 2024 sales view might have initially caused some concerns but was overshadowed by the overall positive sentiment towards the company.
• The activist pressure from Icahn Enterprises may have initially raised some uncertainties, but the market seemed to focus more on the company's long-term growth potential and resilience.